Strategies for intranasal delivery of vaccines
Open Access
- 12 July 2012
- journal article
- review article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 3 (1) , 100-109
Abstract
The vast majority of human pathogens colonize and invade at the mucosal surfaces. Preventing infection at these sites via mucosally active vaccines is a promising and rational approach for vaccine development. However, it is only recently that the stimulation of local immunity at the mucosal surfaces has become a primary objective in addition to inducing systemic immunity. This review describes vaccine formulations designed for mucosal delivery to the nasal-associated lymphoid tissue, via intranasal administration. The association of antigens with mucosal adjuvants and delivery systems is emphasised.Keywords
This publication has 114 references indexed in Scilit:
- Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid ProteinMolecular Pharmaceutics, 2012
- Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic CellsCancer Research, 2011
- Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunityMucosal Immunology, 2011
- The Nasal Dendritic Cell-Targeting Flt3 Ligand as a Safe Adjuvant Elicits Effective Protection against Fatal Pneumococcal PneumoniaInfection and Immunity, 2011
- Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccineVaccine, 2011
- Intranasal DNA Vaccination Induces Potent Mucosal and Systemic Immune Responses and Cross-protective Immunity Against Influenza VirusesMolecular Therapy, 2011
- Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responsesBMC Immunology, 2010
- Effects of the TLR2 Agonists MALP-2 and Pam3Cys in Isolated Mouse LungsPLOS ONE, 2010
- Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate SystemsJournal of Pharmaceutical Sciences, 2009
- New strategies for using mucosal vaccination to achieve more effective immunizationVaccine, 1994